308 related articles for article (PubMed ID: 38140174)
1. A Multi-Center Study Investigating Long COVID-19 in Healthcare Workers from North-Eastern Italy: Prevalence, Risk Factors and the Impact of Pre-Existing Humoral Immunity-ORCHESTRA Project.
Cegolon L; Mauro M; Sansone D; Tassinari A; Gobba FM; Modenese A; Casolari L; Liviero F; Pavanello S; Scapellato ML; Taus F; Carta A; Spiteri G; Monaco MGL; Porru S; Larese Filon F
Vaccines (Basel); 2023 Nov; 11(12):. PubMed ID: 38140174
[No Abstract] [Full Text] [Related]
2. SARS-CoV-2 Reinfections in Health-Care Workers, 1 March 2020-31 January 2023.
Cegolon L; Magnano G; Negro C; Larese Filon F;
Viruses; 2023 Jul; 15(7):. PubMed ID: 37515237
[No Abstract] [Full Text] [Related]
3. Primary SARS-CoV-2 Infections, Re-infections and Vaccine Effectiveness during the Omicron Transmission Period in Healthcare Workers of Trieste and Gorizia (Northeast Italy), 1 December 2021-31 May 2022.
Cegolon L; Negro C; Mastrangelo G; Filon FL;
Viruses; 2022 Nov; 14(12):. PubMed ID: 36560692
[No Abstract] [Full Text] [Related]
4. COVID-19 in City Council Civil Servants, 1 March 2020-31 January 2023: Risk of Infection, Reinfection, Vaccine Effectiveness and the Impact of Heterologous Triple Vaccination.
Cegolon L; Larese Filon F
Vaccines (Basel); 2024 Feb; 12(3):. PubMed ID: 38543888
[No Abstract] [Full Text] [Related]
5. Risk of Vaccine Breakthrough SARS-CoV-2 Infection and Associated Factors in Healthcare Workers of Trieste Teaching Hospitals (North-Eastern Italy).
Basso P; Negro C; Cegolon L; Larese Filon F
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215930
[No Abstract] [Full Text] [Related]
6. COVID-19 Incidence and Vaccine Effectiveness in University Staff, 1 March 2020-2 April 2022.
Cegolon L; Negro C; Pesce M; Filon FL
Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851360
[No Abstract] [Full Text] [Related]
7. Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study.
Babouee Flury B; Güsewell S; Egger T; Leal O; Brucher A; Lemmenmeier E; Meier Kleeb D; Möller JC; Rieder P; Rütti M; Schmid HR; Stocker R; Vuichard-Gysin D; Wiggli B; Besold U; McGeer A; Risch L; Friedl A; Schlegel M; Kuster SP; Kahlert CR; Kohler P;
PLoS Med; 2022 Nov; 19(11):e1004125. PubMed ID: 36342956
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 immunity and reasons for non-vaccination among healthcare workers from eastern and northern Switzerland: results from a nested multicentre cross-sectional study.
Albrecht S; Grässli F; Cusini A; Brucher A; Goppel S; Betschon E; Möller JC; Ortner M; Ruetti M; Stocker R; Vuichard-Gysin D; Besold U; Risch L; Von Kietzell M; Schlegel M; Vernazza P; Kuster SP; Kahlert CR; Kohler P
Swiss Med Wkly; 2024 Apr; 154():3734. PubMed ID: 38689545
[TBL] [Abstract][Full Text] [Related]
9. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life.
Cegolon L; Pol R; Simonetti O; Larese Filon F; Luzzati R
Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242504
[No Abstract] [Full Text] [Related]
10. SARS-CoV-2 incidence, transmission and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-2021.
Cohen C; Kleynhans J; von Gottberg A; McMorrow ML; Wolter N; Bhiman JN; Moyes J; du Plessis M; Carrim M; Buys A; Martinson NA; Kahn K; Tollman S; Lebina L; Wafawanaka F; du Toit J; Xavier Gómez-Olivé F; Dawood FS; Mkhencele T; Sun K; Viboud C; ; Tempia S
medRxiv; 2021 Dec; ():. PubMed ID: 34909794
[TBL] [Abstract][Full Text] [Related]
11. Persistence of Symptoms 15 Months since COVID-19 Diagnosis: Prevalence, Risk Factors and Residual Work Ability.
Sansone D; Tassinari A; Valentinotti R; Kontogiannis D; Ronchese F; Centonze S; Maggiore A; Cegolon L; Filon FL
Life (Basel); 2022 Dec; 13(1):. PubMed ID: 36676046
[No Abstract] [Full Text] [Related]
12. Inappropriate risk perception for SARS-CoV-2 infection among Italian HCWs in the eve of COVID-19 pandemic.
Riccò M; Vezzosi L; Balzarini F; Bragazzi NL
Acta Biomed; 2020 May; 91(3):e2020040. PubMed ID: 32921735
[TBL] [Abstract][Full Text] [Related]
13. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.
Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Lye DC; Tan KB
Lancet Infect Dis; 2023 Jul; 23(7):799-805. PubMed ID: 36924786
[TBL] [Abstract][Full Text] [Related]
14. Clinical Characteristics and Potential Risk Factors Associated with the SARS-CoV-2 Infection: Survey on a Health Care Workers (HCWs) Population in Northern Italy.
Novelli V; Fassio F; Resani G; Bussa M; Durbano A; Meloni A; Oliva G; Cutti S; Girardi D; Odone A; Villani S; Marena C; Muzzi A; Monti MC
Int J Environ Res Public Health; 2022 Jul; 19(13):. PubMed ID: 35805853
[TBL] [Abstract][Full Text] [Related]
15. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
[TBL] [Abstract][Full Text] [Related]
16. Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral Variant and Vaccination Status: A Multicenter Cross-Sectional Study.
Kahlert CR; Strahm C; Güsewell S; Cusini A; Brucher A; Goppel S; Möller E; Möller JC; Ortner M; Ruetti M; Stocker R; Vuichard-Gysin D; Besold U; McGeer A; Risch L; Friedl A; Schlegel M; Vernazza P; Kuster SP; Kohler P;
Clin Infect Dis; 2023 Jul; 77(2):194-202. PubMed ID: 36905145
[TBL] [Abstract][Full Text] [Related]
17. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
18. [Antibody Response After Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: A Prospective Observational Study].
Özgür D; Tütüncü EE
Mikrobiyol Bul; 2022 Jan; 56(1):36-48. PubMed ID: 35088958
[TBL] [Abstract][Full Text] [Related]
19. Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers.
Ali AM; Tofiq AM; Rostam HM; Ali KM; Tawfeeq HM
J Med Virol; 2022 Dec; 94(12):5867-5876. PubMed ID: 36029103
[TBL] [Abstract][Full Text] [Related]
20. Differences in Motivating Factors for SARS-CoV-2 Vaccination and Perceptions of Infection Risk among Healthcare and EMS Personnel in South Carolina.
Gormley MA; Nolan MS; Heo M; Litwin AH; Alier A; Daguise V
South Med J; 2022 Jun; 115(6):381-387. PubMed ID: 35649524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
